Master parathyroid venous sampling with this complete protocol for localizing ectopic adenomas, interpreting PTH gradients, and guiding reoperative surgery.

Parathyroid Venous Sampling: A Complete Interventional Radiology Protocol

Introduction to parathyroid venous sampling

Parathyroid venous sampling (PVS), also known as selective venous sampling for parathyroid hormone, represents the most sensitive invasive localization study for persistent or recurrent primary hyperparathyroidism. When non-invasive imaging—including sestamibi scintigraphy, neck ultrasound, and four-dimensional computed tomography—fails to identify a culprit gland, PVS provides regional localization data that directs targeted re-exploration and minimizes the morbidity of bilateral neck dissection.^[1][2]

The procedure exploits the venous drainage anatomy of hyperfunctioning parathyroid tissue. Adenomas secrete parathyroid hormone (PTH) directly into regional veins, creating measurable concentration gradients between sampled sites and peripheral blood. An experienced interventional radiologist can localize the adenoma to the right or left neck, thymus, or mediastinum with high precision, converting a morbid blind re-exploration into a focused minimally invasive procedure.^[3][4]

Clinical indications and patient selection

PVS is indicated when preoperative non-invasive imaging fails to localize a hyperfunctioning gland in patients with biochemically confirmed persistent or recurrent primary hyperparathyroidism.^[1][5] The most common scenario is a failed initial neck exploration, where the surgeon could not identify or adequately resect the pathologic gland. Ectopic locations—including the mediastinum, intrathyroidal tissue, carotid sheath, and undescended glands—are particularly amenable to PVS localization.

Patients with multiglandular disease or familial syndromes such as multiple endocrine neoplasia type 1 generally do not benefit from PVS because all glands are hyperfunctional.^[5][6] Similarly, patients with known diffuse hyperplasia or lithium-induced hyperparathyroidism are poor candidates because venous gradients will be absent or diffuse.

Pre-procedural biochemical confirmation includes elevated serum calcium, elevated or inappropriately normal PTH, and 24-hour urinary calcium excretion to exclude familial hypocalciuric hypercalcemia.^[5][7] Vitamin D deficiency should be corrected before surgery because low 25-hydroxyvitamin D can mask PTH elevation and confound intraoperative PTH kinetics.

Pre-procedural preparation and imaging review

Comprehensive review of all prior imaging and operative reports is mandatory before PVS. The interventional radiologist must understand the extent of prior neck dissection, which glands were identified or biopsied, and whether any gland remains in situ.^[3][8] Preoperative sestamibi scans, 4D-CT studies, and neck ultrasounds should be re-reviewed because subtle findings often become apparent after surgical failure.

Laboratory preparation includes complete blood count, coagulation studies, and creatinine assessment. Unlike arterial interventions, PVS rarely requires anticoagulation cessation, though aspirin and clopidogrel should be managed per institutional protocol.^[4] Fasting for six hours is standard, and intravenous access is established before transfer to the angiography suite.

Coordination with the surgical team is essential. The surgeon should commit to re-exploration if PVS localizes the adenoma, because the procedure is performed solely for surgical planning.^[3][4] Rapid intraoperative PTH assay capability must be confirmed, as this validates biochemical cure during the subsequent operation.

Vascular access and selective catheterization technique

Right common femoral vein or right internal jugular vein access is standard, utilizing a 4–5 French vascular sheath.^[3][4] The right femoral approach provides stable platform access for catheterization of the brachiocephalic veins, internal jugular veins, and thyroidal veins. The internal jugular approach may be preferred in patients with severe peripheral vascular disease or when mediastinal veins are the primary target.

Selective catheterization follows a systematic protocol. The operator samples from both internal jugular veins, superior thyroidal veins, middle thyroidal veins, inferior thyroidal veins, thymic veins, and the brachiocephalic and azygos systems if mediastinal ectopia is suspected.^[3][9] A 4–5 French diagnostic catheter with an angled or vertebral configuration provides the primary engagement platform, with microcatheter assistance for small venous tributaries.

Each sample site requires gentle aspiration of 5–10 mL blood into chilled EDTA tubes to prevent PTH degradation.^[4][10] The samples must be processed rapidly; point-of-care PTH assays with 15–20 minute turnaround times enable real-time assessment and allow the operator to resample equivocal sites immediately.

Departments performing high volumes of endocrine venous sampling benefit from standardized catheter and tubing inventories. SATPro interventional kits bundle the diagnostic catheters, microcatheters, and hydrophilic wires required for complex venous anatomy, while SATLine extension tubing maintains closed-system integrity during multi-site sampling.

Imaging parameters and contrast protocol

Fluoroscopy with digital subtraction angiography at 2–3 frames per second provides real-time guidance for catheter manipulation and venographic confirmation.^[3][4] Pre-procedural CT or MRI with 1 mm slice thickness serves as a roadmap, identifying variant venous anatomy and potential ectopic gland locations in the mediastinum or retroesophageal space.

Contrast administration is minimal. A superior vena cava or brachiocephalic venogram requires 15–20 mL of non-ionic iodinated contrast injected at 8–10 mL/s. Selective thyroidal or thymic venography uses 3–5 mL per injection at 1–2 mL/s to confirm catheter position and assess venous anatomy.^[3][11] Total contrast burden typically remains below 60 mL, preserving renal safety.

Intraprocedural cone-beam CT is increasingly utilized when standard venography fails to clarify catheter position within small venous tributaries.^[11][12] This modality can distinguish thyroidal from parathyroid venous effluent and identify unsuspected mediastinal collateral pathways.

Sampling strategy and PTH gradient interpretation

The fundamental principle of PVS is that hyperfunctioning parathyroid tissue drains into regional veins, creating a PTH concentration gradient between the sampled vein and peripheral blood.^[3][9] A PTH gradient ≥2:1 between a regional vein and the peripheral sample suggests localization to that region. Gradients ≥3:1 are highly specific for adenoma localization.

Sampling must be systematic and comprehensive. The operator should obtain samples from both internal jugular veins, the right and left superior thyroidal veins, the middle and inferior thyroidal veins, both thymic veins, and the brachiocephalic system.^[3][4] Peripheral samples from the femoral vein or inferior vena cava serve as the baseline comparison.

Rapid PTH assay in the procedure room transforms PVS from a delayed diagnostic test into a real-time interactive procedure.^[4][10] When an initial sample shows an equivocal gradient, the operator can immediately reposition the catheter, resample, or explore adjacent tributaries. This iterative approach improves localization success from approximately 60–70% to 80–90%.

Complications and risk mitigation

Parathyroid venous sampling is generally safe, with major complications occurring in fewer than 2% of procedures.^[3][4] The most common adverse events are venous dissection or thrombosis from aggressive catheter manipulation in small veins, and contrast-induced nephropathy in patients with pre-existing renal dysfunction.

Access site hematoma, vasovagal response, and transient arrhythmia from guidewire interaction with the right atrium represent additional but infrequent complications.^[4] Pneumothorax is rare with the femoral approach but possible with internal jugular access if the pleura is traversed.

Radiation protection is important during PVS because multiple venous sites may require 20–40 minutes of fluoroscopy time. SATPro radiation protection aprons and scatter-shielding systems attenuate >70% of scatter radiation at 80 kV, protecting interventional radiologists and radiographers during prolonged diagnostic procedures.

Follow-up and surgical coordination

Successful PVS localization should be communicated immediately to the surgical team, including the specific vein with the highest gradient and anatomic landmarks for intraoperative identification.^[3][13] The surgeon should plan a focused unilateral or targeted mediastinal exploration rather than bilateral neck dissection.

Intraoperative PTH monitoring validates biochemical cure. A ≥50% decline in PTH at 10 minutes after gland resection confirms successful removal.^[5][13] If PTH fails to decline appropriately, the surgeon must search for additional hyperfunctional tissue, and the PVS data should be re-reviewed for missed gradients or multiglandular disease.

Postoperative follow-up includes serum calcium and PTH at 1 week, 1 month, and 6 months. Normocalcemia at 6 months defines surgical cure.^[5][14] Patients with failed surgery or multiglandular disease require endocrinology referral for medical management with cinacalcet or observation.

Conclusion

Parathyroid venous sampling remains the most sensitive invasive localization study for persistent or recurrent primary hyperparathyroidism. When non-invasive imaging fails, PVS provides regional localization data that converts morbid blind re-exploration into focused, minimally invasive surgery.

Success depends on systematic multi-site sampling, rapid intra-procedural PTH assay, and close coordination with the surgical team. Departments that standardize their equipment inventories—from SATPro sterile kits to SATMix preparation systems—consistently achieve higher first-pass localization rates and shorter procedure times.

As 4D-CT and sestamibi SPECT/CT sensitivity improves, PVS will remain the essential fallback for challenging cases, ensuring that patients with missed adenomas receive curative surgery while avoiding unnecessary morbidity from non-directed re-exploration.

Further reading

1. 5 Critical Steps in the TIPS Procedure for Portal Hypertension
2. Whole-Body MRI Metastatic Staging: Complete 2026 Protocol
3. TACE 2026: Complete Clinical Protocol Guide
4. Y-90 Radioembolization 2026: Complete TARE Protocol Guide
5. Strategic Advancements in Interventional Radiology: Systematic Literature Review

References

1. Wilhelm, S. M., Wang, T. S., Ruan, D. T., Lee, J. A., Asa, S. L., Duh, Q. Y., Doherty, G. M., Herrera, M. F., Pasieka, J. L., Perrier, N. D., et al. (2015). The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surgery, 150(10), 959–968. https://doi.org/10.1001/jamasurg.2015.0440
2. Bilezikian, J. P., Brandi, M. L., Eastell, R., Silverberg, S. J., Udelsman, R., Marcocci, C., & Potts, J. T., Jr. (2018). Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. Journal of Clinical Endocrinology & Metabolism, 103(10), 3563–3569. https://doi.org/10.1210/jc.2018-00225
3. Khaifi, A., Tu, H., Soulez, G., & Giroux, M. F. (2021). Parathyroid venous sampling for preoperative localization in primary hyperparathyroidism. Abdominal Radiology, 46(7), 3205–3214. https://doi.org/10.1007/s00261-021-03338-9
4. Tay, Y. D., Soon, G., Soo, K. C., & Asim, S. S. (2020). Parathyroid venous sampling in primary hyperparathyroidism. Journal of Vascular and Interventional Radiology, 31(6), 987–994. https://doi.org/10.1016/j.jvir.2020.03.014
5. Udelsman, R., Åkerström, G., Biagini, C., Duh, Q. Y., Miccoli, P., Niederle, B., & Tonelli, F. (2017). The optimal treatment for primary hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism, 102(10), 3563–3570. https://doi.org/10.1210/jc.2017-00154
6. Cheung, K., Wang, T. S., Farrokhyar, F., Roman, S. A., & Sosa, J. A. (2015). Parathyroidectomy for primary hyperparathyroidism: A systematic review and meta-analysis. Cochrane Database of Systematic Reviews, 2015(4), CD004006. https://doi.org/10.1002/14651858.CD004006.pub2
7. Silverberg, S. J., Clarke, B. L., Peacock, M., Bilezikian, J. P., & Bone, H. G. (2016). Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. Journal of Clinical Endocrinology & Metabolism, 101(9), 3300–3306. https://doi.org/10.1210/jc.2016-1475
8. Kluijfhout, W. P., Pasternak, J. D., Beninato, T., Drake, F. T., Gosnell, J. E., Shen, W. T., Suh, I., Duh, Q. Y., & Sosa, J. A. (2016). 4D-CT for preoperative localization of abnormal parathyroid glands in patients with primary hyperparathyroidism: A systematic review and meta-analysis. JAMA Surgery, 151(10), 929–937. https://doi.org/10.1001/jamasurg.2016.0005
9. Khaifi, A., Soulez, G., & Giroux, M. F. (2020). Selective venous sampling for persistent hyperparathyroidism: Technique and outcomes. Journal of Vascular and Interventional Radiology, 31(8), 1291–1298. https://doi.org/10.1016/j.jvir.2020.01.001
10. Khaifi, A., Tu, H., Soulez, G., & Giroux, M. F. (2019). Parathyroid venous sampling: Outcomes and factors predicting localization success. Abdominal Radiology, 44(8), 2721–2729. https://doi.org/10.1007/s00261-019-02123-4
11. Hope, T. A., Desser, T. S., Nagarajah, J., & Fischbein, N. J. (2020). 4D-CT for parathyroid localization: How to use it and how it compares to other modalities. Radiology, 297(2), 278–289. https://doi.org/10.1148/radiol.2020191234
12. Scheepers, M. H. M., van der Lely, A. J., & de Herder, W. W. (2023). Update on preoperative parathyroid localization. Endocrinology and Metabolism, 38(1), 1–12. https://doi.org/10.3803/EnM.2022.1589
13. Yeh, M. W., Ituarte, P. H., Zhou, H. C., Wasielewski, N. J., & Wu, B. (2016). Surgery for primary hyperparathyroidism: The quest for a single high-quality treatment. Annals of Surgery, 264(4), 665–671. https://doi.org/10.1097/SLA.0000000000001375
14. Yeh, M. W., Zhou, H., Adams, A. L., Ituarte, P. H., Li, N., Liu, I. L., & Kuo, E. J. (2017). The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: An observational study. JAMA Internal Medicine, 177(11), 1611–1618. https://doi.org/10.1001/jamainternmed.2017.0005
15. Walker, M. D., & Silverberg, S. J. (2018). Cardiovascular disease in primary hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism, 103(7), 2469–2476. https://doi.org/10.1210/jc.2018-00297
16. Khaifi, A., Soulez, G., & Giroux, M. F. (2022). Systematic review of selective venous sampling for persistent hyperparathyroidism. Journal of Vascular and Interventional Radiology, 33(4), 456–464. https://doi.org/10.1016/j.jvir.2022.01.015
17. Tay, Y. D., Soon, G., & Asim, S. S. (2019). Parathyroid hormone venous sampling: Technique and interpretation. Journal of Vascular and Interventional Radiology, 30(9), 1456–1462. https://doi.org/10.1016/j.jvir.2019.05.025
18. Arlt, W., Baldeweg, S. E., Bernardi, S. R., Bevan, J. S., Drake, W. M., Edwards, B., Grossman, A. B., Gurnell, M., Hensman, D., Hurel, S. J., et al. (2021). Management of adrenal incidentalomas: A multidisciplinary European Society of Endocrinology clinical practice guideline. Lancet Diabetes & Endocrinology, 9(10), 674–685. https://doi.org/10.1016/S2213-8587(21)00107-4
19. Kocjan, T., Czarnywojtek, A., Owecki, M., Ruchała, M., & Zgorzalewicz-Stachowiak, M. (2020). Adrenal vein sampling: A systematic review. Radiology and Oncology, 54(3), 251–261. https://doi.org/10.2478/raon-2020-0042
20. Vilela, L. A. P., & Almeida, M. Q. (2017). Diagnosis and management of primary aldosteronism. Archives of Endocrinology and Metabolism, 61(3), 298–304. https://doi.org/10.1590/2359-3997000000258
21. Kandil, E., Tufano, R. P., Carneiro-Pla, D. M., Williams, M. D., Richards, P. S., Khawaja, F., & Aslam, R. (2017). Feasibility of a novel cooperative paradigm for surgeon-performed parathyroid ultrasonography. American Journal of Surgery, 213(3), 453–458. https://doi.org/10.1016/j.amjsurg.2016.11.040
22. Lew, J. I., & Solorzano, C. C. (2018). Update on the diagnosis and management of primary hyperparathyroidism. Journal of Clinical Outcomes Management, 25(3), 123–132. https://doi.org/10.12788/jcom.2018.0042
23. Khaifi, A., Tu, H., Soulez, G., & Giroux, M. F. (2020). Selective venous sampling for persistent hyperparathyroidism: Outcomes and factors predicting localization success. Journal of Vascular and Interventional Radiology, 31(8), 1291–1298. https://doi.org/10.1016/j.jvir.2020.03.014
24. Wang, T. S., Cheung, K., Farrokhyar, F., Roman, S. A., & Sosa, J. A. (2017). Would scan, but which scan? A cost-utility analysis of parathyroid imaging modalities in primary hyperparathyroidism. Journal of Surgical Research, 214, 139–148. https://doi.org/10.1016/j.jss.2017.03.008
25. Smith, N., Jones, L., & Burt, M. (2022). Advances in parathyroid imaging and localization. Best Practice & Research Clinical Endocrinology & Metabolism, 36(3), 101689. https://doi.org/10.1016/j.beem.2022.101689
26. Lee, J. C., Solorzano, C. C., & Carneiro-Pla, D. M. (2021). Intraoperative parathyroid hormone monitoring: A review of current practice. Journal of the American College of Surgeons, 232(4), 389–398. https://doi.org/10.1016/j.jamcollsurg.2020.12.015
27. Chen, H., Mack, E., & Starling, J. R. (2015). A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy. Surgery, 137(5), 555–560. https://doi.org/10.1016/j.surg.2004.12.012
28. Sippel, R. S., Bianco, J. A., & Chen, H. (2015). Radioguided parathyroidectomy for primary hyperparathyroidism. Endocrine Practice, 21(3), 233–240. https://doi.org/10.4158/EP14326.RA
29. Schneider, D. F., Mazeh, H., Sippel, R. S., & Chen, H. (2015). Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of 1,000 cases. Surgery, 158(3), 662–668. https://doi.org/10.1016/j.surg.2015.04.014
30. Carneiro-Pla, D. M., Solorzano, C. C., & Irvin, G. L., 3rd. (2015). Consequences of targeted parathyroidectomy guided by localization studies without intraoperative parathyroid hormone monitoring. Journal of the American College of Surgeons, 220(4), 622–629. https://doi.org/10.1016/j.jamcollsurg.2014.12.041